Robalzotan

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRobalzotan
Drug Alias Name洛巴佐坦robalzotanum罗巴佐坦AZD-7371NAD-299
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor antagonists
TargetsSerotonin 1a (5-HT1a) receptor
Therapy Area/IndicationsAnxietyDepressionUrinary Bladder, Overactive +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsAnxietyDepressionUrinary Bladder, Overactive +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia